Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
- PMID: 33016930
- PMCID: PMC7598076
- DOI: 10.1172/JCI134132
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
Abstract
The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively _targeted MYCN-amplified neuroblastoma via multiple mechanisms. CDK9 - a component of the transcription elongation complex P-TEFb - bound to the MYCN-amplicon superenhancer, and its inhibition resulted in selective loss of nascent MYCN transcription. MYCN loss led to growth arrest, sensitizing cells for apoptosis following CDK2 inhibition. In MYCN-amplified neuroblastoma, MYCN invaded active enhancers, driving a transcriptionally encoded adrenergic gene expression program that was selectively reversed by CYC065. MYCN overexpression in mesenchymal neuroblastoma was sufficient to induce adrenergic identity and sensitize cells to CYC065. CYC065, used together with temozolomide, a reference therapy for relapsed neuroblastoma, caused long-term suppression of neuroblastoma growth in vivo, highlighting the clinical potential of CDK9/2 inhibition in the treatment of MYCN-amplified neuroblastoma.
Keywords: Cancer; Oncology; Transcription; Translation.
Conflict of interest statement
Figures
Similar articles
-
CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.Cell Cycle. 2013 Apr 1;12(7):1091-104. doi: 10.4161/cc.24091. Epub 2013 Mar 5. Cell Cycle. 2013. PMID: 23462184 Free PMC article.
-
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12968-73. doi: 10.1073/pnas.0901418106. Epub 2009 Jun 12. Proc Natl Acad Sci U S A. 2009. PMID: 19525400 Free PMC article.
-
Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.Int J Cancer. 2020 Oct 1;147(7):1928-1938. doi: 10.1002/ijc.32936. Epub 2020 Mar 16. Int J Cancer. 2020. PMID: 32086952
-
Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or MYCN gene.J Clin Pathol. 2023 Aug;76(8):518-523. doi: 10.1136/jcp-2022-208476. Epub 2023 May 23. J Clin Pathol. 2023. PMID: 37221048 Review.
-
Didymin: an orally active citrus flavonoid for _targeting neuroblastoma.Onco_target. 2017 Apr 25;8(17):29428-29441. doi: 10.18632/onco_target.15204. Onco_target. 2017. PMID: 28187004 Free PMC article. Review.
Cited by
-
Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights.Cell Rep Med. 2022 May 17;3(5):100632. doi: 10.1016/j.xcrm.2022.100632. Cell Rep Med. 2022. PMID: 35584622 Free PMC article. Review.
-
TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.Cancer Sci. 2023 Jul;114(7):2860-2870. doi: 10.1111/cas.15815. Epub 2023 Apr 24. Cancer Sci. 2023. PMID: 37094904 Free PMC article.
-
Antagonistic effect of cyclin-dependent kinases and a calcium-dependent phosphatase on polyglutamine-expanded androgen receptor toxic gain of function.Sci Adv. 2023 Jan 6;9(1):eade1694. doi: 10.1126/sciadv.ade1694. Epub 2023 Jan 6. Sci Adv. 2023. PMID: 36608116 Free PMC article.
-
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.Leukemia. 2022 Jun;36(6):1596-1608. doi: 10.1038/s41375-022-01553-w. Epub 2022 Apr 5. Leukemia. 2022. PMID: 35383271 Free PMC article.
-
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by _targeting Superenhancer-Related Genes in Neuroblastoma.J Immunol Res. 2022 Nov 16;2022:7945884. doi: 10.1155/2022/7945884. eCollection 2022. J Immunol Res. 2022. PMID: 36438198 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- 22897/CRUK_/Cancer Research UK/United Kingdom
- MC_PC_18051/MRC_/Medical Research Council/United Kingdom
- 091763Z/10/Z/WT_/Wellcome Trust/United Kingdom
- C34648/A28278/CRUK_/Cancer Research UK/United Kingdom
- C1060/A10334/CRUK_/Cancer Research UK/United Kingdom
- C1090/A16464/CRUK_/Cancer Research UK/United Kingdom
- 27725/CRUK_/Cancer Research UK/United Kingdom
- C34648/A18339/CRUK_/Cancer Research UK/United Kingdom
- 16464/CRUK_/Cancer Research UK/United Kingdom
- MC_PC_16047/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- 14610/CRUK_/Cancer Research UK/United Kingdom
- R01 CA215452/CA/NCI NIH HHS/United States
- C309/A11566/CRUK_/Cancer Research UK/United Kingdom
- 23302/CRUK_/Cancer Research UK/United Kingdom
- 28278/CRUK_/Cancer Research UK/United Kingdom
- C24461/A23302/CRUK_/Cancer Research UK/United Kingdom
- DH_/Department of Health/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous